Xcout Intel
Laguna Pharmaceuticals, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Laguna Pharmaceuticals, Inc. among biotechnology companies — ranked by similarity to what Laguna Pharmaceuticals, Inc. actually does, not by market-cap band.
Subscribe to see Laguna Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Laguna Pharmaceuticals, Inc.
Laguna Pharmaceuticals is a biotechnology company developing precision microbial immunotherapy platforms to treat various cancers, including high-risk leukemias and soft-tissue sarcomas. The company utilizes engineered, highly attenuated microbial vectors to activate and expand innate T cells directly within the body, aiming to overcome immune evasion by tumors.
Laguna Pharmaceuticals, Inc. at a glance
Laguna Pharmaceuticals, Inc. is a biotechnology company headquartered in United States. It has raised at least $34.5M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $30M in February 2015. Xcout tracks 2 named people at Laguna Pharmaceuticals, Inc., including Jonathan Kotula (CEO and Co-Founder).
Laguna Pharmaceuticals, Inc. leadership
- Jonathan KotulaCEO and Co-Founder
- Russell CarringtonCOO and Co-Founder
Laguna Pharmaceuticals, Inc. funding rounds
At least $34.5M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $30M | — | |
| SEC Form D filing | $4.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Laguna Pharmaceuticals, Inc. competitors
Ranked by semantic similarity — how close each company is to Laguna Pharmaceuticals, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Biotech
Elicera Therapeutics is a clinical-stage immuno-oncology company that develops genetically engineered cell and gene therapies, including CAR T-cell therapies and oncolytic viruses, to treat various types of cancer. The company utilizes its proprietary iTANK technology platform to enhance the immune system's ability to target and attack solid tumors.
Biotech
Altamira Therapeutics Ltd. is a biotechnology company developing RNA-based cancer therapies using its proprietary xPhore nanoparticle delivery technology. Its lead candidate, ATX-402, is designed to systemically deliver therapeutic mRNA to reprogram the tumor microenvironment and improve cancer immunotherapy outcomes for patients.
Similar biotechnology company
Core Biomedicine is a preclinical-stage biotechnology and pharmaceutical manufacturing company pioneering lineage-based precision oncology therapeutics.
Biotech
ArsenalBio is a biotechnology company developing programmable cell therapies, particularly engineered T-cell therapies, for cancer treatment. It serves biopharmaceutical and healthcare markets by using synthetic biology and genomic engineering to create more effective, controllable immune-cell medicines.
Similar biotechnology company
Laverock Therapeutics is a biotechnology research company headquartered in London, England, that develops programmable advanced therapies.
Similar biotechnology company
OneChain Immunotherapeutics is a biotechnology company based in Barcelona focused on the development of CAR-T cell therapies and in vivo platforms for cancer immunotherapy.
Similar biotechnology company
A2 Biotherapeutics, Inc. is a clinical-stage biotechnology research company headquartered in Agoura Hills, California. The company develops precision T-cell therapies designed to target solid tumors while sparing healthy tissue.
Biotech
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.
Biotech
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
Life Sciences
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Similar biotechnology company
KiraGen Bio is a Boston-based biotechnology company pioneering the development of AI-driven, multiplex gene-edited CAR-T cell therapies designed to target and block tumor suppression.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Laguna Pharmaceuticals, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Laguna Pharmaceuticals, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →